Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet promising study from Memorial Sloan Kettering Cancer Center.

For media inquiries contact: Sudha Sruthi, Corporate Development email us here ...

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

The annual BioTech Breakthrough Awards program evaluates top companies, solutions, and products in the global life sciences and biotechnology markets. This year's program attracted thousands of ...

Predicting how cancer patients will respond to treatment remains a critical challenge. Immune checkpoint inhibitors (ICIs), a ...

The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative ...

Pancreatic cancer, one of the most aggressive and lethal types of cancer, continues to present significant challenges in both its detection and treatment. The lack of early detection tools, coupled ...

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...